RxDoctor Payments Data

Ellendale Gabbert

Family · Sulphur, LANPI 1134337017

Payments from drug & device makers

$5,028in general payments, 2019–2025

Across 250 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$732
  • Merck$670
  • Novartis$643
  • AstraZeneca$488
  • Pfizer$351
  • Amgen$251
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,94998%
  • Education$792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,028 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$87,399
Medicare patients
410
Services billed
2,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$294,096
XareltoRivaroxaban101$113,376
CamzyosMavacamten12$98,799
EntrestoSacubitril/Valsartan75$70,671
Repatha SureclickEvolocumab81$57,010
JardianceEmpagliflozin63$52,452
FarxigaDapagliflozin Propanediol44$25,785
Repatha SyringeEvolocumab18$12,173
Praluent PenAlirocumab15$9,319
Ezetimibe278$5,128
Metoprolol Succinate304$4,865
Atorvastatin Calcium399$3,984
Ranolazine ErRanolazine42$3,245
ClopidogrelClopidogrel Bisulfate218$2,538
Digoxin55$2,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$351$294,096342 claims
Johnson & JohnsonXarelto$144$113,376101 claims
E.r. Squibb & Sons, L.L.C.Camzyos$215$98,79912 claims
NovartisEntresto$643$70,67175 claims
Boehringer IngelheimJardiance$142$52,45263 claims
AstraZenecaFarxiga$488$25,78544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.

Other family in Sulphur

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →